Apart from the targeted therapy which has been described above, early stage NSCLC wild type for EGFR and ALK can benefit from neoadjuvant and/or adjuvant immunotherapy or immunochemotherapy in the context of ongoing large phase 3 clinical trials [3,6,12,13,17]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.